CAR-T Cell Therapy in India — Availability, Centres and Cost

CAR-T cell therapy is available in India at a small number of accredited centres, concentrated in Mumbai, Delhi NCR, Bengaluru, Chennai, Hyderabad and a few other large cities. It is not offered at every cancer hospital. Access is by referral to a haemato-oncology unit licensed to deliver gene-modified cell therapy.

Why so few centres. The reprogrammed cells multiply inside the body after infusion. That expansion can cause severe reactions in the first two weeks. A centre is only permitted to infuse if it can keep the medicines that treat those reactions on site, staff a unit that recognises them early, and provide intensive-care backup in the same building. That requirement, not lack of demand, is what limits the list.

What changed the picture. A CD19-directed CAR-T therapy developed and manufactured in India received CDSCO market authorisation in 2023, and is delivered through a growing but still limited network of accredited hospitals. Before that, families in India were looking at internationally approved products that are largely not marketed here, which meant travelling abroad and paying an international list price. That is the single biggest reason this question is worth re-asking in 2026.

What has not changed. The number of centres is still small relative to the country, the queue at each one is real, and eligibility is narrow. Being able to afford it and being able to reach it are two separate problems, and families usually meet both at once.

Said plainly, before anything else: CION Cancer Clinics does not provide CAR-T cell therapy or any other cell therapy. We do not administer it, stock it or manufacture it, and we quote no price for it. This page exists so you can understand what you are being asked to plan for, and so we can point you to an accredited centre if your diagnosis is one where CAR-T is genuinely on the table.

There is no single price. For the CAR-T therapy manufactured in India, the cell product alone has been reported in the region of ₹30 lakh to ₹45 lakh, indicative, as of August 2026. Testing, collection, hospital stay and monitoring are billed on top. Internationally approved products are reported at several crore rupees.

Read these as planning ranges, not a quotation. None of it is a rate offered by CION against any product, and no product is named on this page. What a family is finally charged depends on the centre, the diagnosis, the amount of bridging treatment needed, and whether a reaction occurs after infusion. The only number you can act on is a written estimate from the treating centre, itemised into product, hospital stay and monitoring. Ask for it before you sign anything, and ask what is excluded.

From referral to infusion, two to four months is the common range in India, and it can run longer. Manufacturing is the predictable part, at roughly two to six weeks. The slow steps sit around it: getting accepted at an accredited centre, and arranging the money. Funding approval is usually the single longest step.

One thing worth planning for honestly: relapsed disease can progress while a batch is being manufactured, and not everyone who starts this pathway reaches the infusion. Centres run bridging treatment for exactly that reason. Ask the centre what its bridging plan is for your case, and what happens if the batch fails release testing.

1. 1

   Referral to an accredited centre

   Your haemato-oncologist writes to a unit licensed to deliver cell therapy and sends the full record: biopsy and marrow reports, immunophenotyping, imaging and every line of treatment given so far. Incomplete records are the commonest reason this step drags.

2. 2

   Eligibility assessment

   The centre checks the diagnosis against approved indications, then checks you: organ function, performance status, active infection, and whether enough healthy T cells can be collected. This is a clinical decision, and a no at this stage is a real outcome. See who is eligible for CAR-T therapy.

3. 3

   Funding is arranged and confirmed in writing

   Nothing proceeds until the money is committed. Insurance pre-authorisation, employer schemes, charitable trusts and crowdfunding all take weeks. Start this on day one, not after eligibility is confirmed, because it is usually the slowest step in the whole pathway.

4. 4

   Cell collection

   Blood passes through a machine that separates out your T cells and returns the rest. It takes a few hours and needs no surgery. The collection is cryopreserved and shipped to the manufacturing site under a tracked chain of identity, because those cells belong to one named person.

5. 5

   Manufacturing, release testing and bridging

   Roughly two to six weeks while the gene is inserted, the cells are grown into a dose, and the batch is tested for sterility, identity, potency and viability. Meanwhile the centre may give bridging treatment to hold the disease steady. A batch that fails cannot be swapped for another.

6. 6

   Conditioning chemotherapy, then the infusion

   A short lymphodepleting course a few days beforehand makes room for the new cells to expand. The infusion itself usually takes under an hour and is anticlimactic to watch. The work is in what follows it.

7. 7

   Weeks of monitoring, then long-term follow-up

   Patients stay at or beside the centre for two to four weeks at minimum, because reactions such as cytokine release syndrome mostly appear early. Regulators then require years of follow-up after gene-modified cell therapy, as long-term data is still maturing.

• Private health insurance — some policies now consider CAR-T, but cover is policy-specific and often capped below the full cost. Insist on written pre-authorisation, not a verbal assurance from a helpline.
• Employer and corporate schemes — group cover, CSR medical assistance and employee welfare funds sometimes contribute. Ask HR for the written policy limit rather than the headline sum insured.
• Charitable trusts and relief funds — hospital-linked trusts, disease-specific foundations and state relief funds assist selected patients. Applications need the centre's estimate attached, so request that estimate first.
• Crowdfunding — widely used in India and genuinely effective for some families, but it takes weeks to mature and should be started in parallel, never after everything else has failed.
• A clinical trial, where one is open — a trial may cover the product itself. Enrolment is never certain, criteria are strict, and no trial should be presented to you as a sure thing.

If a relative abroad is funding treatment, factor in transfer timelines, documentation the centre will need for foreign remittances, and the fact that the patient still has to be physically at the centre for weeks. CION does not receive payment for CAR-T and is not a party to any of these arrangements.

• What is the itemised written estimate? Product, hospital stay, monitoring and reaction treatment listed separately, with what is excluded stated.
• What is your current turnaround? Real dates from acceptance to infusion at this centre, not a generic range from a brochure.
• What is the bridging plan? What holds the disease steady while the batch is made, and what it will cost.
• What happens if the batch fails release testing? Whether collection is repeated, who pays for the repeat, and how long it adds.
• What is the realistic picture for my exact diagnosis? Expected benefit and its limits, in writing, for this disease and this line of treatment.
• What does follow-up require? How long you must stay near the centre, and what long-term monitoring is mandatory afterwards.

No. CION Cancer Clinics does not administer, stock or manufacture CAR-T cell therapy or any other cell therapy, and quotes no price for it. If a page, an agent or a forwarded message tells you otherwise, it is wrong.

What we do is read your reports and give you a straight answer: whether your diagnosis is even in a category where CAR-T gets discussed, what the pathway would realistically demand of your family, and what the treatment you have already been offered is worth as a written second opinion. Where referral to an accredited cell-therapy centre is the right next step, we will say so and help you prepare the record.

The immunotherapy given as day care at CION centres is checkpoint-inhibitor treatment — a different class of treatment, with a different mechanism, schedule and side-effect pattern. Response-assessment PET-CT during that treatment is coordinated at partner imaging centres rather than owned by CION. Our first consultation is free, takes 45 minutes, and carries no commitment to start treatment anywhere.

• How CAR-T Therapy Works, Step by Step — the laboratory side of the pathway above, which is also the clearest explanation of why a batch of one costs what it does.
• Who Is Eligible for CAR-T Therapy? — read this before you raise money, because eligibility is decided on diagnosis, prior treatment and fitness, and a no here ends the cost question.
• Cytokine Release Syndrome (CRS): The Main CAR-T Complication — the reaction that explains the weeks of monitoring, the accredited-centre rule, and a large part of the hospital bill.
• Immunotherapy at CION Cancer Clinics — the treatments CION does provide, how eligibility is assessed, and what a free first consultation actually covers.

This page is general information and does not replace a consultation. CION Cancer Clinics does not provide CAR-T or any cell therapy; immunotherapy at CION means checkpoint-inhibitor treatment given as day care, with response-assessment PET-CT coordinated at partner imaging centres. No product is named on this page. All cost and timing figures are indicative, as of August 2026, and drawn from published manufacturer and news reports rather than a CION rate card. Clinical framing follows NCCN and ESMO patient-education guidance and the CDSCO position in India. Only your treating haemato-oncologist, reviewing your complete case, can tell you what applies to you.

Most families reach this page weighing an impossible number against hope

Ask us what your diagnosis actually calls for. You will get a plain answer, including when the answer is that CAR-T is not relevant to your case.